<DOC>
	<DOCNO>NCT02140112</DOCNO>
	<brief_summary>This randomize , double-blind , 2-arm , placebo-controlled crossover study pediatric patient autism spectrum disorder patient receive 16-weeks TSO treatment 16 week placebo .</brief_summary>
	<brief_title>Efficacy Safety Trichuris Suis Ova ( TSO ) Compared Placebo Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Male female patient , 5 17 year age Patients must fulfill DSMV diagnostic criterion autism spectrum disorder ascertain screening , use clinical review confirm Autism Diagnosis Observation Schedule Second edition ( ADOS2 ) Written informed consent parent ( ) legal guardian ( ) sufficient intellectual capacity understand study support patient ' adherence study procedure must obtain patient emancipate . In accordance Institutional Review Board ( IRB ) requirement , patient complete inform assent developmentally appropriate , participate study conduct studyspecific procedure . Patients able willing swallow study medication suspension . Known diagnosis syndromal form Autism ( e.g . Rett Syndrome , Childhood Disintegrative Disorder , Fragile X Syndrome , etc . ) Patients discontinue antipsychotic medication Patients current active seizure disorder seizure within last 6 month prior screen Female patient pregnant breastfeeding wish become pregnant study participation unwilling use birth control . Patients receive helminthic treatment</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>T. suis ovum</keyword>
	<keyword>Trichuris suis ovum</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>ASD</keyword>
</DOC>